Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.35 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.34 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL117063 | 1.00 | LMNA (0.39) | LMNATP53HTTPDE2ACA1 | |
| Hydrochloric Acid SCHEMBL29873729 | 1.00 | LMNA (0.39) | LMNATP53HTTPDE2ACA1 | |
| Hydrochloric Acid SCHEMBL22659695 | 1.00 | LMNA (0.39) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL31683735 | 0.98 | LMNA (0.41) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL16793738 | 0.98 | LMNA (0.41) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL121332 | 0.98 | LMNA (0.41) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL31683734 | 0.98 | LMNA (0.41) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL8164587 | 0.98 | LMNA (0.41) | LMNATP53HTTPDE2ACA1 | |
| SCHEMBL169458 | 0.82 | DPP8 (0.32) | LMNATP53HTTCA1CA2 | |
| Hydrochloric Acid SCHEMBL5783861 | 0.81 | GRM1 (0.33) | LMNACA1CA2HRH4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4051680-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-08-18 | — | — | US | disclosed |
| EP-3969124-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | CA2 2315/4885GLA 2680/4885HTR2A 4511/4885 |
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, TEC | CA2 1391/4885GLA 3578/4885HTR2A 3939/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | CA2 3043/4885GLA 2826/4885HTR2A 3034/4885 |
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | CA2 2559/4885GLA 3292/4885HTR2A 2342/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | CA2 2559/4885GLA 3292/4885HTR2A 2342/4885 |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | CA2 2315/4885GLA 2680/4885HTR2A 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.